Literature DB >> 15234456

Ex vivo proton MR spectroscopy (1H-MRS) for evaluation of human gastric carcinoma.

Chi-Woong Mun1, Ji-Youn Cho, Woon-Jae Shin, Ki-Seung Choi, Choong-Ki Eun, Seong Sook Cha, Junghee Lee, Young Il Yang, Sang-Hee Nam, Jeongkoo Kim, Soo Yeol Lee.   

Abstract

The present study was performed to determine the characteristics of the biochemical metabolites related to gastric cancer using ex vivo (1)H magnetic resonance spectroscopy (MRS), and to assess the clinical usefulness. A total of 35 gastric specimens resected during surgery for gastric cancer were used to compare MR spectra. A 1.5-T (64-MHz) clinical MR imager equipped with facilities for spectroscopy was used to obtain MR spectra from 33 gastric specimens. High-resolution (1)H nuclear magnetic resonance (NMR) spectra of the remains of two specimens were also examined with a 9.4-T (400-MHz) NMR spectrometer. Localized spectroscopic measurements were performed in two layers of gastric tissue, the proper muscle layer and the composite mucosa/submucosa layer. T(2) FSE and 3D SPGR images were used to determine the voxel size and the location for MRS data collection. MR spectra were obtained using the single-voxel PRESS technique with parameters of TR/TE = 2000/30 ms, NA = 256, and voxel size = 3 x 3 x 3 mm(3) (27 microL). Cancerous and noncancerous gastric tissues in the voxel were determined by histopathological analysis. On 9.4-T ex vivo NMR spectroscopy, the following metabolite peaks were found: lipids at 0.9 ppm (CH(3)) and 1.3 ppm (CH(2)); alanine (beta-CH(3)) at 1.58 ppm; N-Acetyl neuraminic acid (NANA: sialic acid) at 2.03 ppm; and glutathione at 2.25 ppm in normal gastric tissue layers. In the 1.5-T MR system, broad and featureless spectral peaks of the various metabolites in normal human gastric tissue were observed at 0.9 ppm, 1.3 ppm, 2.0 ppm, and 2.2 ppm regardless of gastric tissue layer. In specimens (Borrmann type III) with tubular adenocarcinoma, resonance peaks were observed at 1.26 ppm, 1.36 ppm (doublet of lactate), and 3.22 ppm (choline). Cancer lesions showed decreased levels of lipid peaks, showing the significant lactate doublet peaks, and increased intensity of the choline peak as compared with noncancerous gastric tissue. We found that decreased levels of lipids and increases in lactate and choline peaks in gastric tissue were markers for malignancy in gastric lesions. Information provided by ex vivo (1)H MRS, together with the development of in vivo (1)H MRS with high field strength and high resolution, may be very useful for the diagnosis of gastric cancer in clinical situation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234456     DOI: 10.1016/j.mri.2004.01.045

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  5 in total

1.  1H-MRS application in the evaluation of response to photo-thermal therapy using iron oxide-gold core-shell nanoparticles, an in vivo study.

Authors:  Sina Ehsani; Erfan Saatchian; Abolfazl Sarikhani; Alireza Montazerabadi
Journal:  Photochem Photobiol Sci       Date:  2021-02-09       Impact factor: 3.982

Review 2.  Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer?

Authors:  Roberto García-Figueiras; Sandra Baleato-González; Anwar R Padhani; Laura Oleaga; Joan C Vilanova; Antonio Luna; Juan Carlos Cobas Gómez
Journal:  Diagn Interv Radiol       Date:  2016 Jan-Feb       Impact factor: 2.630

Review 3.  MRS-based Metabolomics in Cancer Research.

Authors:  Tedros Bezabeh; Omkar B Ijare; Alexander E Nikulin; Rajmund L Somorjai; Ian Cp Smith
Journal:  Magn Reson Insights       Date:  2014-02-13

4.  Cytotoxicity of TSP in 3D Agarose Gel Cultured Cell.

Authors:  Song-I Chun; Chi-Woong Mun
Journal:  PLoS One       Date:  2015-06-09       Impact factor: 3.240

5.  A systematic review of metabolomic profiling of gastric cancer and esophageal cancer.

Authors:  Sha Huang; Yang Guo; Zhexuan Li; Yang Zhang; Tong Zhou; Weicheng You; Kaifeng Pan; Wenqing Li
Journal:  Cancer Biol Med       Date:  2020-02-15       Impact factor: 4.248

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.